# Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

> **NCT07461441** · PHASE3 · RECRUITING · sponsor: **Yeungnam University College of Medicine** · enrollment: 50 (estimated)

## Conditions studied

- Polypoidal Choroidal Vasculopathy (PCV)
- Age Related Macular Degeneration

## Interventions

- **DRUG:** Faricimab Injection [Vabysmo]

## Key facts

- **NCT ID:** NCT07461441
- **Lead sponsor:** Yeungnam University College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07461441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07461441, "Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07461441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*